GSK Releases Ris-Rez Cancer Drug Trial Data
The pharmaceutical company announced promising results from a phase Ib clinical trial for patients with relapsed lung cancer.
Updated on Oct. 21, 2026 in Cancer
Live Poll
Is the pace of medical innovation for terminal cancer patients currently adequate to meet clinical needs?
GSK has released preliminary data from its EMBOLD PanTumour-101 trial, showing an objective response rate of 61% for patients receiving an 8 mg/kg dose of the drug Ris-Rez. The study evaluated the treatment in 50 patients with relapsed extensive-stage small cell lung cancer.
Why it matters
Patients diagnosed with extensive-stage small cell lung cancer often experience rapid relapse and have a limited selection of effective treatment options. This trial provides a new potential therapy for individuals who have already exhausted prior treatment lines.
The study recorded a 42% rate of grade 3 or higher treatment-related adverse events at the 8 mg/kg dose, compared to 15% at the 6 mg/kg dose level. Researchers also documented a 2% rate of interstitial lung disease across all participants.
The players
GSK
GSK is a multinational pharmaceutical and biotechnology company that focuses on research and development of vaccines and medicines.
ESMO Congress
The ESMO Congress is an annual international medical conference dedicated to advancements in oncology and cancer research.
The details
The EMBOLD PanTumour-101 trial administered Ris-Rez as an intravenous infusion every three weeks to patients who had received a median of two prior therapies. GSK has selected the 8 mg/kg dosage for upcoming phase III trials to further investigate its efficacy as a monotherapy for solid tumours.
Timeline
October 21, 2026: Trial data presented at the ESMO Congress in Madrid, Spain.
The Big Picture
This report on the EMBOLD PanTumour-101 trial marks a critical step in evaluating new targeted therapies for advanced small cell lung cancer. The data serves to validate the ongoing efforts to expand monotherapy options within oncology research programs.
The selection of an 8 mg/kg dose for future trials helps define clearer treatment parameters for clinicians treating relapsed cancer. Patients may see these results influence upcoming clinical trial availability as GSK shifts focus toward larger phase III studies.
The takeaway
This trial offers a potentially significant option for lung cancer patients who have seen little progress with traditional therapies. Continued monitoring of safety data remains essential as the drug moves into larger-scale phase III trials.
What happens next
GSK plans to initiate phase III trials for Ris-Rez in patients with early-line small cell lung cancer and chemo-naïve metastatic castration-resistant prostate cancer, with a broader goal of evaluating the drug across more than 40 indications by 2040.
Further reading
For more information on the latest developments in oncology, visit our Cancer section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Is the pace of medical innovation for terminal cancer patients currently adequate to meet clinical needs?
